What top creators are saying about Recursion Pharmaceuticals, Inc.(RXRX)
Biotechnology company
8 AI-extracted insights from 4 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Not enough scored insights about Recursion Pharmaceuticals, Inc. in the last 30 days yet.
Top creators covering Recursion Pharmaceuticals, Inc. (RXRX)
The 4 sources with the most insights about Recursion Pharmaceuticals, Inc. on Kazuha.
Latest insights about Recursion Pharmaceuticals, Inc. (RXRX)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Tuesday, February 17, 2026
NVIDIA's 13F filing revealed it sold its entire stake in the company as part of a portfolio rebalancing.
Friday, December 26, 2025
JPMorgan upgraded the stock to Overweight, citing blockbuster potential for its drug REC-4881 and strong efficacy for REC-617, suggesting a potential 3x return.
Tuesday, December 9, 2025
Identified as a potential short squeeze candidate due to a 30% short interest and positive AI-developed drug data, despite dilution concerns. A 'max bearish' call from Jim Cramer is noted as a potential contrarian indicator.
Monday, December 8, 2025
Announced positive Phase 1b/2 results for its AI-developed drug REC-4881. Considered a potentially attractive opportunity due to positive news, investor interest from NVIDIA, and high (40%) short interest.
Thursday, December 4, 2025
Set to release critical clinical data from its TUPELO Phase 1b/2 trial on December 8, 2025. The decision to host a webinar suggests potential confidence in positive data, which could trigger a significant price movement and a potential short squeeze.
Monday, September 15, 2025
NVIDIA's investment in the company highlights a strategic interest in the application of AI for drug discovery and the broader healthcare sector.
Monday, July 21, 2025
Mentioned as one of the heavily shorted, smaller-cap stocks that saw significant gains due to a 'risk-on' appetite and speculative fervor in the market.
Monday, July 7, 2025
Speaker is shorting the stock and believes it is 'basically worthless'.
Tuesday, February 17, 2026
NVIDIA's 13F filing revealed it sold its entire stake in the company as part of a portfolio rebalancing.
Friday, December 26, 2025
JPMorgan upgraded the stock to Overweight, citing blockbuster potential for its drug REC-4881 and strong efficacy for REC-617, suggesting a potential 3x return.
Tuesday, December 9, 2025
Identified as a potential short squeeze candidate due to a 30% short interest and positive AI-developed drug data, despite dilution concerns. A 'max bearish' call from Jim Cramer is noted as a potential contrarian indicator.
Monday, December 8, 2025
Announced positive Phase 1b/2 results for its AI-developed drug REC-4881. Considered a potentially attractive opportunity due to positive news, investor interest from NVIDIA, and high (40%) short interest.
Thursday, December 4, 2025
Set to release critical clinical data from its TUPELO Phase 1b/2 trial on December 8, 2025. The decision to host a webinar suggests potential confidence in positive data, which could trigger a significant price movement and a potential short squeeze.
Monday, September 15, 2025
NVIDIA's investment in the company highlights a strategic interest in the application of AI for drug discovery and the broader healthcare sector.
Monday, July 21, 2025
Mentioned as one of the heavily shorted, smaller-cap stocks that saw significant gains due to a 'risk-on' appetite and speculative fervor in the market.
Monday, July 7, 2025
Speaker is shorting the stock and believes it is 'basically worthless'.
Discussed alongside Recursion Pharmaceuticals, Inc. (RXRX)
Other assets that creators frequently mention in the same content as Recursion Pharmaceuticals, Inc..
Frequently asked
Which podcasters and creators cover Recursion Pharmaceuticals, Inc. (RXRX) the most?
The most active sources covering Recursion Pharmaceuticals, Inc. (RXRX) on Kazuha are beaniemaxi, @amitinvesting, @realmartinshkreli, PodcastAI. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Recursion Pharmaceuticals, Inc. (RXRX) are on Kazuha?
Kazuha has indexed 8 AI-extracted insights about Recursion Pharmaceuticals, Inc. (RXRX) from 4 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Recursion Pharmaceuticals, Inc. (RXRX)?
Creators covering Recursion Pharmaceuticals, Inc. (RXRX) most frequently also discuss NVDA, AAPL, BTC, ARM, GOOGL. See the "Discussed alongside" section above for full asset pages.